Stock Events

Stock Events

Oruka Therapeutics 

€80.50
54
-€8.50-9.55% Friday 15:30

Statistics

Day High
92.5
Day Low
92.5
52W High
92.5
52W Low
54
Volume
1
Avg. Volume
-
Mkt Cap
5.33B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 24
€1.46
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18NovExpected
Q1 2026
Q2 2026
Next
-0.5
-0.47
-0.44
-0.41
Expected EPS
-0.49967905128
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-91.27MNet Income

Analyst Ratings

102.82Average Price Target
The highest estimate is 151.76.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HQ1.XETRA. It's not an investment recommendation.
NVIDIA
7
NVDA
Johnson & Johnson
6
JNJ
Microsoft
5
MSFT
Amazon
5
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm that develops cardiovascular drugs, competing directly with ARCA's heart failure treatments.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops a wide range of medications including those for cardiovascular diseases, directly competing with ARCA's portfolio.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that offers products in various therapeutic areas including cardiology, competing with ARCA's heart-related therapies.
Merck
MRK
Mkt Cap366B
Merck produces medications for various conditions, including heart diseases, making it a competitor in the cardiovascular space.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb develops a range of prescription medicines, including those for cardiovascular diseases, competing with ARCA.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences focuses on antiviral drugs and other medications, including heart disease treatments, competing with ARCA.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, a research-based biopharmaceutical company, has a portfolio that includes cardiovascular drugs, competing with ARCA.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for cardiovascular diseases, competing with ARCA.
Sanofi
SNY
Mkt Cap107.39B
Sanofi focuses on healthcare solutions including cardiovascular diseases, directly competing with ARCA's therapeutic area.

About

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Show more...
CEO
Lawrence Otto Klein
Employees
68
Country
United States
ISIN
US6876041087
WKN
000A3DPH3

Listings

XETRA
DE
HQ1.XETRA
STU
DE
HQ1.STU
MU
DE
HQ1.MU
XNAS
US
ORKA

0 Comments

Share your thoughts

FAQ

What is Oruka Therapeutics stock price today?▼
The current price of HQ1.XETRA is €80.50 EUR — it has decreased by -9.55% in the past 24 hours. Watch Oruka Therapeutics stock price performance more closely on the chart.
What is Oruka Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Oruka Therapeutics stocks are traded under the ticker HQ1.XETRA.
What is Oruka Therapeutics market cap?▼
Today Oruka Therapeutics has the market capitalization of 5.33B
When is the next Oruka Therapeutics earnings date?▼
Oruka Therapeutics is going to release the next earnings report on November 18, 2026.
What were Oruka Therapeutics earnings last quarter?▼
HQ1.XETRA earnings for the last quarter are -0.48 EUR per share, whereas the estimation was -0.44 EUR resulting in a -7.32% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Oruka Therapeutics revenue for the last year?▼
Oruka Therapeutics revenue for the last year amounts to 0 EUR.
What is Oruka Therapeutics net income for the last year?▼
HQ1.XETRA net income for the last year is -91.27M EUR.
Does Oruka Therapeutics pay dividends?▼
Yes, HQ1.XETRA dividends are paid en. The last dividend per share was 1.46 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Oruka Therapeutics have?▼
As of September 01, 2026, the company has 68 employees.
In which sector is Oruka Therapeutics located?▼
Oruka Therapeutics operates in the Health & Wellness sector.
When did Oruka Therapeutics complete a stock split?▼
Oruka Therapeutics has not had any recent stock splits.
Where is Oruka Therapeutics headquartered?▼
Oruka Therapeutics is headquartered in MENLO PARK, United States.